Clearmind Medicine Inc. has announced the initiation of a Phase I/IIa clinical trial for its proprietary drug candidate, CMND-100, aimed at treating Alcohol Use Disorder (AUD). The trial marks a significant step as the first participant has been dosed under controlled clinical settings. This multinational, multicenter study, conducted at prominent institutions such as Yale School of Medicine and Johns Hopkins University, seeks to establish the safety and optimal dosing of CMND-100. Additionally, it will explore early signals of efficacy, including reductions in alcohol consumption and cravings. The results of this trial have not yet been presented, as the study is ongoing.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.